Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer. Francis KE, Simon S, Gebski V, Joly F, et al. Gynecol Oncol 2024;192:50-55.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Francis KE, Simon S, Gebski V, Joly F, et al. Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer. Gynecol Oncol 2024;192:50-55.
PMID: 39536691